Table 2 Association of PET metrics with DDIR status, pathological response and recurrence.

From: A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma

 

U-statistic

Unadjusted p-value

Adjusted p-value

DDIR status

Baseline SUVmax

979.00

0.40

1.00

Post-NACT SUVmax

1347.00

0.09

0.26

Change in SUVmax

885.50

0.14

0.42

Pathological response

Baseline SUVmax

513.00

0.22

0.66

Post-NACT SUVmax

934.50

0.01

0.03

Change in SUVmax

268.50

0.0006

0.002

Recurrence

Baseline SUVmax

1842.00

0.15

0.46

Post-NACT SUVmax

1593.00

1.00

1.00

Change in SUVmax

1690.50

0.58

1.00